NASDAQ:EDSA

Edesa Biotech Earnings Date & Estimates

Edesa Biotech logo
$2.17 +0.11 (+5.34%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 -0.11 (-5.07%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edesa Biotech is estimated to report earnings on Friday, December 11, 2026.

What Analysts Expect from Edesa Biotech

Edesa Biotech is expected to post earnings of -$0.58 per share. In the same quarter a year earlier Edesa Biotech reported $0.53 per share on revenue of $247.15 thousand. Edesa Biotech last reported on August 13, 2026, posting -$0.60 per share and missing the -$0.4350 consensus estimate. Edesa Biotech has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.58
Prior-Year EPS
$0.53
Prior-Year Revenue
$247.15 thousand
Expected EPS Growth
-209.4%

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
-$0.60 (Missed by -$0.1650)
EPS Beat Rate
3 of last 8 quarters

Edesa Biotech Earnings FAQ

Edesa Biotech (NASDAQ:EDSA) is estimated to report earnings on Friday, December 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Edesa Biotech to post earnings of -$0.58 per share for the quarter.

Edesa Biotech Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Edesa Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email.

About Edesa Biotech

Edesa Biotech (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. The company’s work centers on biologic drug candidates designed to address conditions with limited treatment options.

Its pipeline has included EB01, a topical treatment candidate for allergic contact dermatitis, and EB05, an antibody candidate being investigated for acute respiratory distress syndrome. These programs are in development and are not approved treatments.

Edesa is based in Markham, Ontario, Canada, and conducts clinical development of its candidates for potential use in international markets.

View Edesa Biotech Profile